Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
John S. Tregoning, Ryan F. Russell & Ekaterina Kinnear. (2018) Adjuvanted influenza vaccines. Human Vaccines & Immunotherapeutics 14:3, pages 550-564.
Read now
Read now
Karen K. Yam, Angela Brewer, Virginie Bleau, Édith Beaulieu, Corey P. Mallett & Brian J. Ward. (2017) Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice. Human Vaccines & Immunotherapeutics 13:3, pages 561-571.
Read now
Read now
Sarah Lartey, Rishi D Pathirana, Fan Zhou, Åsne Jul-Larsen, Emanuele Montomoli, John Wood & Rebecca Jane Cox. (2015) Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics 11:7, pages 1654-1662.
Read now
Read now
Keith S Reisinger, Sandra J Holmes, Paola Pedotti, Ashwani Kumar Arora & Maria Lattanzi. (2014) A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Human Vaccines & Immunotherapeutics 10:8, pages 2395-2407.
Read now
Read now
Pierre Van Damme, Froukje Kafeja, Vinod Bambure, Emmanuel Hanon, Philippe Moris, François Roman & Paul Gillard. (2013) Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine. Human Vaccines & Immunotherapeutics 9:7, pages 1512-1522.
Read now
Read now
Articles from other publishers (5)
Nuriban Valero-Pacheco, Marisol Pérez-Toledo, Miguel Ángel Villasís-Keever, Adriana Núñez-Valencia, Ilka Boscó-Gárate, Bernardo Lozano-Dubernard, Horacio Lara-Puente, Clara Espitia, Celia Alpuche-Aranda, Laura C. Bonifaz, Lourdes Arriaga-Pizano, Rodolfo Pastelin-Palacios, Armando Isibasi & Constantino López-Macías. (2016) Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine. PLOS ONE 11:2, pages e0150146.
Crossref
Crossref
Airi Poder, Pavol Simurka, Ping Li, Sumita Roy-Ghanta & David Vaughn. (2014) An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10–17 years of age. Vaccine 32:9, pages 1121-1129.
Crossref
Crossref
Meliha C Kapetanovic, Lars-Erik Kristensen, Tore Saxne, Teodora Aktas, Andreas Mörner & Pierre Geborek. (2014) Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Research & Therapy 16:1, pages R2.
Crossref
Crossref
Odile Launay, Xavier Duval, Serge Fitoussi, Wolfgang Jilg, Angkool Kerdpanich, May Montellano, Tino F Schwarz, Veerachai Watanveerade, Jürgen J Wenzel, Gerard Zalcman, Vinod Bambure, Ping Li, Adrian Caplanusi, Anuradha Madan, Paul Gillard & David W Vaughn. (2013) Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infectious Diseases 13:1.
Crossref
Crossref
William H. Yang, Marc Dionne, Michael Kyle, Naresh Aggarwal, Ping Li, Miguel Madariaga, Olivier Godeaux & David W. Vaughn. (2013) Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial. Vaccine 31:40, pages 4389-4397.
Crossref
Crossref